FS KKR Capital is a middle market credit vehicle whose stock trades far below the book value its sponsor wrote into a preferred conversion price. The gap between the two numbers is the entire story, and the spring 2026 restructuring is the attempt to close it. The company is one of the larger externally advised BDCs, and its book is dominated by senior secured middle market loans.
The stock stood near $11.98 in early September, and the book at the second quarter mark was $18.30 per share. That is a 35 percent discount, wide by sector standards. In the same half the sponsor completed a large unsecured bond, bought $150 million of preferred, ran a fixed price tender for common, authorized a $300 million buyback, and waived half of its income incentive fee. The question is whether the discount is a mispricing or the true cost of a capital stack the market does not trust.
FS KKR Capital Corp. is a Maryland business development company listed on the NYSE. It lends primarily to private companies in the middle market, weighted to senior secured debt with a smaller share of subordinated loans, asset based finance, and equity. The vehicle is externally managed, and the investment decisions run through FS/KKR Advisor, a partnership of Future Standard and KKR Credit.
Michael C. Forman, a former Goldman Sachs partner, serves as CEO and Chairman. Daniel R. Pietrzak is President and Chief Investment Officer and is also a KKR partner and Global Head of Private Credit, a dual role that puts the sponsor inside the investment committee. The spring 2026 restructuring is the defining event for the stock, and it came after a quarter that marked down the book and pushed non accruals to their cycle high.
First quarter book value fell from $20.89 to $18.83 per share, and net investment income slipped in the same period. On May 11 the board announced four moves at once, plus a fee waiver, in a single announcement that set the agenda for the rest of the year. The mechanism matters more than the parts, because the bond, the revolver amendment, the preferred, and the buyback all had to work together to change the balance sheet.
The bond, issued at 7.50 percent due 2031, replaced floating and secured funding with fixed unsecured debt. The revolver was amended to shrink commitments and to reset the equity floor from roughly $5.05 billion down to $3.75 billion. That reset gives the balance sheet room to absorb further marks without a covenant squeeze, which is the whole point of a de leveraging package. The bear reads the same moves differently: when KKR buys preferred at $18.83 while common trades near $11, the sponsor is long the asset at a price above market, and the tender, the buyback, and the fee waiver all shrink the common claim on a portfolio still being marked down.
FSK does not sell a product. It originates and holds loans, and the moat is the underwriting platform behind them. At the second quarter mark the book was $11.4 billion, of which 58.7 percent was first lien senior secured. The remainder was second lien, subordinated debt, asset based finance, a joint venture position, and equity, with the joint venture alone at 14.4 percent of fair value.
Roughly 59 percent of the book is variable rate, which reprices with short term rates and hedges the asset side against a higher for longer environment. The weighted average yield on accruing debt was 9.8 percent at the second quarter mark. That small compression from the prior quarter is consistent with a quality over yield trade rather than a breakdown in pricing, which is the distinction the portfolio commentary keeps drawing.
The KKR relationship is the platform moat, and it cuts both ways. FSK inherits deal flow, co investment rights, and servicing infrastructure from one of the largest private credit franchises in the country. At the same time the relationship means that deal pricing, co investment allocation, and advisory fees are all negotiated inside a structure where the sponsor sits on both sides. The Credit Opportunities Partners joint venture lets FSK leverage originations without holding the full credit risk, but it adds a second layer of related party economics that outside holders can only evaluate through disclosure.
The top ten names represented 21 percent of fair value at the second quarter mark, elevated for a vehicle this size. A handful of single name downgrades can move the book more than an average portfolio would suggest. The non accrual rate was 3.4 percent at year end and rose to 4.2 percent at the first quarter mark. It then eased back to 3.8 percent at the second quarter mark, a path that shows a book still working through a cycle of stress. The moat is real but shallow: it is the sponsor s platform, not a structural barrier that keeps the discount from staying wide.
The income line carries the distribution but not the discount. Net investment income was $0.42 per share in the first quarter, and it rose to $0.44 in the second. Coverage sits at about 1.0x with the fee waiver doing real work on the second quarter number, and the board declared $0.44 per share for the third quarter, payable in early October. On a $11.98 stock the trailing yield is near 17 percent, a level that only holds if the income floor holds and the buyback keeps the share count shrinking.
The book value line is where it gets uncomfortable. NAV per share moved from $20.89 at year end to $18.83 at the first quarter mark. That is a drop of $2.06, and it then fell further to $18.30 at the second quarter mark. The first quarter draw included $2.00 per share of net realized and unrealized losses, of which $1.99 was the adjusted figure after merger accounting. The company attributed the decline to legacy positions that had already impaired, new non accrual names, and spread widening in certain segments, and by the second quarter the losses had moderated to $0.56 per share.
The common equity base at the second quarter mark was $5.1 billion, and the debt load was $6.5 billion. That is a 127 percent gross leverage ratio, with 72 percent of the debt unsecured. Cash and availability were $109 million plus $3.1 billion of undrawn capacity. The capital changes in the half all moved in one direction: replace floating and secured funding with fixed unsecured, buy common below book, and push sponsor capital into the preferred line.
About $40 million of repurchases landed in late June and early August at an average of $10.73. The derivative suits are a dynamic in their own right, and repeated filings of shareholder derivative actions ran through the spring and summer. The June current report carried director change and shareholder matter items. The suits typically allege that the board failed to protect the company from related party value leakage in the spring restructuring. They do not change the book math, but they add a contingent cost and a governance overhang that sits on top of the portfolio risk, and they slow the pace at which future related party moves can be made.
The forward case rests on four levers the sponsor can actually pull, and each one is conditional. The first is the buyback, authorized at $300 million through June of next year. About $40 million was spent in the first six weeks at an average of $10.73. If the program runs at that pace and the stock holds below $12, the share count shrinks by roughly 5 percent over the next two quarters, which lifts book value per share mechanically even if the portfolio is flat. The risk is that the buyback is conditional on maintaining net repayment levels and total leverage, so a portfolio stress that forces a pause removes the very catalyst the bull case depends on.
The second lever is the fee waiver, which covers half of the subordinated income incentive fee and runs through the first quarter of next year. It is non recoupable, a one way ratchet in the company s favor, but it is also a temporary support for net investment income. If income without the waiver is structurally below $0.44 per share, the third and fourth quarter distributions either compress or coverage drops, and the 17 percent yield that anchored the discount becomes a distribution cut risk. The execution risk is that the waiver masks a portfolio yield that is still compressing, and the market may price that compression into the discount before the buyback can offset it.
The third lever is the portfolio rotation, and the company trimmed the book by roughly $850 million in the second quarter. It cut non accruals from 4.2 to 3.8 percent of fair value. First lien senior secured was pushed to 58.7 percent of the book. The direction is right, but the rotation is happening while the company raises unsecured debt at 7.50 percent. The spread between that coupon and the accruing yield is about 230 basis points before fees, and that spread is the cushion the income line is built on. If the book rotates into lower yielding, higher quality credit, the spread narrows and the per share income floor that supports the distribution comes under pressure.
The fourth lever is the sponsor preferred, a $150 million convertible at an $18.83 conversion that gives KKR an as converted voting block and the right to elect two directors as a separate class. After six months the holder can convert, and after six years it can force redemption. If the stock trades near $11 for the next two years the preferred sits as a permanent 5 percent cash drag that steps up over time, and it ranks senior to common on dividends. If the stock recovers toward $18, the conversion price becomes a real overhang because the sponsor can convert and sell, capping the upside. The counterargument on execution is that the hard part is done: the balance sheet is de levered, the bond is fixed, the fee is waived, the buyback is authorized, and the book is rotating. What remains is portfolio execution over four quarters, which is a normal operating question, and the bear response is that a normal operating question on a book that lost $2 of value in one quarter is not a small ask.
The primary risk is portfolio credit, and it is the risk that moved the stock from $17.90 to $9.72. That is a range over the trailing 52 weeks that shows the middle market credit book is not a low volatility asset class. The first quarter book value draw of $2.06 per share, driven by legacy impairments, new non accruals, and spread widening, shows how fast the book can move when credit conditions turn. A single name downgrade can move the book by a meaningful share of its value given the top ten concentration, and a second quarter of impairments at the same severity would take NAV below $16.50 per share. The discount would widen even if the stock price held, which is the scenario that would most hurt the thesis.
The second risk is the capital stack, and the cost base is roughly $7 billion of debt against an $11.4 billion portfolio. The $900 million bond and the $150 million preferred at a stepping up dividend sit on top of the amended revolver. The net leverage of 122 percent is inside the regulatory limit and inside the company s target, but it leaves little room for a portfolio draw that would force the company to stop the buyback or to raise equity at the current discount. The unsecured mix is a strength in a going concern scenario because it avoids collateral haircuts, but it is a weakness in distress because unsecured creditors have no asset to seize, which leaves the common deeply subordinated to the entire debt load.
The third risk is the sponsor conflict, the target of the derivative suits. KKR sits on both sides of the preferred, the tender, the joint venture, and the advisory agreement. The 5.5 year step up on the preferred dividend means the sponsor s cost of its own investment rises if the stock stays depressed, which creates an incentive to manage the stock toward the conversion price rather than to maximize common book value. The two board seats the preferred can elect, and the as converted voting, give the sponsor a structural voice in any future related party transaction. The suits carry a contingent cost, but the larger overhang is the governance question they raise about whether the spring restructuring was run for the common or for the sponsor.
The fourth risk is the distribution, and a 17 percent yield on the current price is only supported if income holds near $0.44 per share and the fee waiver persists. If the waiver expires at the end of the first quarter of next year and income without it is $0.38 to $0.40 per share, the board either cuts the distribution or coverage drops, and the yield thesis that anchored the discount collapses. The down side scenario combines a modest second wave of impairments, an end to the fee waiver, and a pause in the buyback. Together they would push book value into the low $17s and the stock into the low $10s, a case in which the discount to book actually widens rather than closes.
The anchor is the discount to book. At $11.98 against $18.30 the stock trades at a wide discount. It is 35 percent below the second quarter book, wider than the roughly 40 percent gap at Main Street Capital. FSK s gap sits at the deep end of the sector, and the question is whether it prices a premium to risk or a capital stack the market does not trust. The framework below carries three scenarios from the second quarter book and a common equity base of $5.1 billion.
The bear case assumes a second wave of impairments brings NAV to $16.80 per share by year end, the fee waiver lapses without a replacement, and the buyback slows on portfolio stress. The common equity base shrinks to roughly $4.6 billion, and the distribution compresses toward $0.38 per share. The stock, if it marks to a wide discount to the lower book, sits near $10.10. That is a downside of about 15 percent from the current price, cushioned by income but not eliminated by it. This is the scenario in which the discount to book widens rather than closes, and it is the one the sponsor is most motivated to avoid.
The base case assumes the portfolio heals as the rotation suggests, non accruals drift back toward a low single digit rate, and the buyback completes the $300 million authorization. NAV stabilizes near $18.30, the fee waiver runs its full four quarters, and the share count shrinks by roughly 8 percent. The stock, if the discount compresses to a quarter of book on a clean third quarter, moves toward $14.25. That is an upside of roughly 19 percent, with a yield at that level of about 12 percent. This is the scenario that justifies the current discount as a mispricing rather than a rational risk premium.
The bull case assumes the rotation outperforms, NAV recovers toward $19.50 by early next year, and the buyback continues past the June expiry on a renewed authorization. The stock moves toward the mid teens, an upside of 30 to 34 percent. The yield compresses to about 10 percent, and the multiple that matters for a BDC is price to book against income coverage. FSK at 0.65x book with 1.0x coverage is cheaper on price than its two largest peers, and the coverage gap is the reason for the discount. The framework implies the stock is fairly valued at the current discount if the portfolio heals and the buyback runs. The quantitative range runs from the low teens to the mid teens around an $18.30 book, and the single most important variable is whether the buyback and the rotation hold through the next two quarters.
FSK is a good portfolio in a contested capital structure, and the discount is the price of the contest. The $11.4 billion book is 59 percent first lien senior secured, variable rate, and rotating into quality, and the income line covers the distribution with the fee waiver doing the work. The balance sheet was reworked in spring 2026 to a fixed unsecured base and de levered to 122 percent net. It was also given a $300 million buyback, and it is being executed at a price below the second quarter book. The average entry has been roughly $10.73 against an $18.30 book. Against that, the sponsor holds the preferred at an $18.83 conversion, the advisory fee, the joint venture, and the deal flow, and the derivative suits say the restructuring was not run for the common.
The judgment is that the stock is fairly valued at the current discount if the portfolio keeps healing and the buyback keeps running, and that the risk reward is asymmetric to the upside only if the third and fourth quarter book value prints confirm the rotation. The discount is not a free option on NAV recovery, because the book itself is a moving target the sponsor has an incentive to manage, and the preferred step up and the fee waiver expiry are dated events that change the income line. The honest read is a 17 percent yield with a 35 percent discount and a sponsor on both sides of the table, and the thesis holds only while the buyback is the dominant force in the book value arithmetic.